• GalGrégoire LeGLDepartment of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, ON, Canada. Electronic address: glegal@toh.ca., Giancarlo Agnelli, Harald Darius, Susan R Kahn, Tarek Owaidah, Ana Thereza Rocha, Zhenguo Zhai, Irfan Khan, Yasmina Djoudi, Ekaterina Ponomareva, and Alexander T Cohen.
• Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, ON, Canada. Electronic address: glegal@toh.ca.
• Eur. J. Intern. Med. 2024 Mar 1; 121: 485548-55.

BackgroundWe aimed to describe the event rates and risk-factors for symptomatic venous thromboembolism (VTE) and major bleeding in a population of hospitalized acutely ill medical patients.MethodsPatients ≥40 years old and hospitalized for acute medical illness who initiated enoxaparin prophylaxis were selected from the US Optum research database. Rates of symptomatic VTE and major bleeding at 90-days were estimated via the Kaplan-Meier (KM) method. Risk factors were identified via the Cox proportional hazards model.ResultsA total of 123,022 patients met the selection criteria. The KM rates of VTE and major bleeding at 90-days were 3.5 % and 2.2 %, respectively. Among subgroups, the risk of VTE varied from 3.0 % in patients with ischemic stroke to 6.9 % in patients with a cancer-related hospitalization, and the risk of major bleeding varied from 1.9 % in patients with inflammatory conditions to 3.6 % in patients with ischemic stroke. Key risk factors for VTE were prior VTE (HR=4.15, 95 % confidence interval [CI] 3.80-4.53), cancer-related hospitalization (HR=2.35, 95 % CI 2.10-2.64), and thrombophilia (HR=1.64, 95 % CI 1.29-2.08). Key risk factors for major bleeding were history of major bleeding (HR=2.17, 95 % CI 1.72-2.74), history of non-major bleeding (HR=2.46, 95 % CI 2.24-2.70), and hospitalization for ischemic stroke (2.42, 95 % CI 2.11-2.78).ConclusionThere is substantial heterogeneity in the event rates for VTE and major bleeding in acute medically ill patients. History of VTE and cancer related hospitalization represent profiles with a high risk of VTE, where continued VTE prophylaxis may be warranted.Copyright © 2023. Published by Elsevier B.V.

22 keywords...

hide…